Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + tremelimumab + oleclumab + ivuxolimab
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination immunotherapy regimen consists of four monoclonal antibodies: durvalumab, tremelimumab, oleclumab (MEDI 9447), and ivuxolimab (MEDI 0562). It is being evaluated in the Phase II umbrella trial NSGO-OV-UMB1 (ENGOT-OV30) for patients with relapsed ovarian, fallopian tube, or peritoneal cancer. Durvalumab targets PD-L1, tremelimumab targets CTLA-4, oleclumab targets CD73 (inhibiting adenosine production), and ivuxolimab is an OX40 agonist. The regimen aims to overcome immune resistance in gynecological cancers by targeting multiple immune checkpoints and pathways simultaneously. The trial is sponsored by the Nordic Society of Gynaecological Oncology - Clinical Trials Unit (NSGO-CTU) in collaboration with AstraZeneca/MedImmune.
- Brand names
- ImfinziImjudo
- Other names
- durvalumab + tremelilumab + MEDI 9447 + MEDI 0562oleclumabivuxolimab
02
Targets
CD28 (Cluster of Differentiation 28)NT5E (Cluster of Differentiation 73)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab + tremelimumab + oleclumab + ivuxolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + tremelimumab + oleclumab + ivuxolimab.